Navigation Links
Long-term pharmacotherapy for obesity and overweight: updated meta-analysis
Date:11/16/2007

Patients taking anti-obesity drugs will only see modest weight loss and many will remain significantly obese or overweight, according to a study published on bmj.com today.

The study, which looked at the long-term effectiveness of anti-obesity medications, found that three drugs recommended for long-term use - orlistat, sibutramine and rimonabant, reduced weight by less than 5kg (11 pounds). This equated to a loss of less than 5% of total body weight. Guidelines from the National Institute for Clinical Excellence recommend stopping the use of anti-obesity drugs if 5% of total body weight is not lost after three months.

While making changes to lifestyle and diet are recommended as the initial treatment for obesity, the use of anti-obesity drugs is common. Its estimated that in 2005 global sales of anti-obesity drugs reached $1.2billion. Current UK guidelines recommend using drug therapy in addition to making lifestyle changes if a patient has a body mass index of greater than 30.

The Canadian researchers reviewed the evidence from thirty placebo-controlled trials where adults took anti-obesity drugs for a year or longer. The mean weight of the volunteers in all of the trials was 100kg (15.7 stone). The mean body mass index levels were 35 36.

Professor Raj Padwal and colleagues found orlistat reduced weight by 2.9kg, sibutramine by 4.2kg and rimonabant by 4.7kg. They also found that patients taking the weight loss pills were significantly more likely to achieve 5 10% weight loss, compared to those who took the placebo.

The health benefits associated with taking the drugs varied. For example, orlistat reduced the incidence of diabetes in one trial and all three drugs lowered patients levels of certain types of cholesterol. Adverse effects were recorded with all three drugs, in particular, rimonabant increased the risk of mood disorders such as depression or anxiety. The authors noted that no trials examined rates of death and disease as a result of taking anti-obesity pills. They recommend that trials looking at this should be carried out in the future.

The authors also noted that there were high drop-out levels in all the trials. On average 30 40% of patients failed to complete the trial. They say this suggests that a failure to properly adhere to the treatment could be a major factor limiting the effectiveness of anti-obesity drug therapy.

In an accompanying editorial, Professor Gareth Williams warns of the potential damage to society if anti-obesity drugs are licensed to be sold without prescription. This already happens in the United States, and as Glaxo Smith Kline (GSK) has applied to sell orlistat over the counter throughout Europe, it could happen here. He warns:

Selling anti-obesity drugs over the counter will perpetuate the myth that obesity can be fixed simply by popping a pill and could further undermine the efforts to promote healthy living, which is the only long term escape from obesity.


'/>"/>

Contact: Emma Dickinson
edickinson@bmj.com
44-020-738-36529
BMJ-British Medical Journal
Source:Eurekalert

Related medicine news :

1. Smoking may strongly increase long-term risk of eye disease
2. Long-Term Fatigue Plagues Cancer Survivors
3. Dont Ignore Tough or Long-Term Stomach Pain
4. Shaking may cause brain damage and serious long-term effects to infants
5. Sexual function affected by stem cell transplant according to long-term study
6. Smoking can harm the long-term effects of some oral surgery procedures
7. Childhood Obesity Epidemic a Long-Term Challenge
8. Conseco to Host Follow-Up Long-Term Care Conference Call
9. New Report Finds Information Technology Essential But Not Sufficient in Long-Term Care
10. No Link Between Amateur Boxing, Long-Term Brain Damage
11. No strong evidence linking amateur boxing with long-term brain injury
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2017)... ... June 24, 2017 , ... The Pennsylvania Athletic Trainers’ ... Bayfront and Erie Convention Center on June 8-10. The weekend consisted of ... bowl, award and scholarship presentations, and professional networking. , On Friday June ...
(Date:6/24/2017)... TX (PRWEB) , ... June 24, 2017 , ... The ... to spend time outdoors. Home and business owners should be aware that the summer ... the lake. In fact, mechanical locks and keys can be negatively affected from direct ...
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... ... Network today announced the launch of Care Management Alerts and Dashboards, an innovative ... patients throughout Rhode Island. , RIQI’s Care Management Alerts and Dashboards provide near ...
(Date:6/23/2017)... ... June 23, 2017 , ... By scoring 100% for ... consecutive four-star rating from premier online charity evaluator, Charity Navigator, validating ANRF's work as ... of all charities reviewed by Charity Navigator and earns ANRF a spot on their ...
(Date:6/23/2017)... ... , ... Studies show evidence that carotenoids and antioxidants derived either from the ... patients. , But how often do ophthalmologists and optometrists in Sweden recommend the use ... or with early symptoms of AMD? A study published recently in Dove ...
Breaking Medicine News(10 mins):
(Date:6/14/2017)... 2017  In 2016, Embodied Labs took ... competition and came away with $25,000 in seed-fund investment. ... Forbes as "entering the life of another" and by ... "empathy to medical professionals in an entirely new dimension." ... a finalist for the Department of Education,s EdSimChallenge, where ...
(Date:6/9/2017)... 9, 2017 AirXpanders, Inc. (ASX: AXP) (AirXpanders ... design, manufacture, sale and distribution of the AeroForm® Tissue ... of its commercial roll-out in the United ... than one hundred (100) medical institutions and health systems, ... a needle-free alternative for women who choose reconstructive surgery ...
(Date:6/7/2017)... , June 7, 2017 Endo International ... June 7, 2017, the Hon. Joseph R. Goodwin ... of West Virginia , entered a ... Inc. Pelvic Repair System Products Liability Litigation (the "MDL") ... MDL cases to provide expert disclosures on specific causation ...
Breaking Medicine Technology: